Skip to main content
Top
Published in: Tumor Biology 12/2016

01-12-2016 | Original Article

RETRACTED ARTICLE: MiR-200 suppresses metastases of colorectal cancer through ZEB1

Authors: Jiwei Sun, Wenjun Ding, Jiajun Zhi, Wei Chen

Published in: Tumor Biology | Issue 12/2016

Login to get access

Abstract

Poor prognosis of some colorectal cancer (CRC) cases largely results from early metastases of CRC to the distal organs. Thus, suppression of the invasion of CRC appears to be crucial therapy. Since microRNAs (miRNAs) play critical roles in the regulation of cancer metastases, identification of the involved miRNAs may provide novel therapeutic targets for CRC treatment. Here, we showed that the levels of miR-200 were significantly decreased and the levels of ZEB1 were significantly increased in the CRC specimens from patients, compared to the paired non-tumor tissue. Moreover, the levels of miR-200 and ZEB1 are inversely correlated. Bioinformatics analyses showed that miR-200 targeted the 3′-UTR of ZEB1 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay. Moreover, miR-200 overexpression inhibited ZEB1-mediated cell invasiveness, while miR-200 depletion increased ZEB1-mediated cell invasiveness in CRC cells. Together, our data suggest that miR-200 suppression in CRC cells may promote ZEB1-mediated cancer metastasis. Our work thus highlights a novel molecular regulatory machinery that regulates metastases of CRC.
Literature
1.
go back to reference East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention–more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.CrossRefPubMed East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention–more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.CrossRefPubMed
2.
go back to reference Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.CrossRefPubMed Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.CrossRefPubMed
3.
go back to reference Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.PubMed Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.PubMed
4.
go back to reference Chai J, Wang S, Han D, Dong W, Xie C, Guo H. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol. 2015;36:1313–21.CrossRefPubMed Chai J, Wang S, Han D, Dong W, Xie C, Guo H. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol. 2015;36:1313–21.CrossRefPubMed
5.
go back to reference Chu D, Zheng J, Li J, Li Y, Zhang J, Zhao Q, et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol. 2014;35:9787–92.CrossRefPubMed Chu D, Zheng J, Li J, Li Y, Zhang J, Zhao Q, et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol. 2014;35:9787–92.CrossRefPubMed
6.
go back to reference Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/beta-catenin pathway downregulating. Tumour Biol. 2015;36:1701–10.CrossRefPubMed Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/beta-catenin pathway downregulating. Tumour Biol. 2015;36:1701–10.CrossRefPubMed
7.
go back to reference Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, et al. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 2015;36:719–27.CrossRefPubMed Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, et al. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 2015;36:719–27.CrossRefPubMed
8.
go back to reference Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, et al. Periostin mediates TGF-beta-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol Biochem. 2015;36:799–809.CrossRefPubMed Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, et al. Periostin mediates TGF-beta-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol Biochem. 2015;36:799–809.CrossRefPubMed
9.
go back to reference Sa Y, Li C, Li H, Guo H. TIMP-1 induces alpha-smooth muscle actin in fibroblasts to promote urethral scar formation. Cell Physiol Biochem. 2015;35:2233–43.CrossRefPubMed Sa Y, Li C, Li H, Guo H. TIMP-1 induces alpha-smooth muscle actin in fibroblasts to promote urethral scar formation. Cell Physiol Biochem. 2015;35:2233–43.CrossRefPubMed
10.
go back to reference Lan A, Qi Y, Du J. Akt2 mediates TGF-beta1-induced epithelial to mesenchymal transition by deactivating GSK3beta/snail signaling pathway in renal tubular epithelial cells. Cell Physiol Biochem. 2014;34:368–82.CrossRefPubMed Lan A, Qi Y, Du J. Akt2 mediates TGF-beta1-induced epithelial to mesenchymal transition by deactivating GSK3beta/snail signaling pathway in renal tubular epithelial cells. Cell Physiol Biochem. 2014;34:368–82.CrossRefPubMed
11.
go back to reference Teng Y, Zhao L, Zhang Y, Chen W, Li X. Id-1, a protein repressed by miR-29b, facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem. 2014;33:717–30.CrossRefPubMed Teng Y, Zhao L, Zhang Y, Chen W, Li X. Id-1, a protein repressed by miR-29b, facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem. 2014;33:717–30.CrossRefPubMed
12.
go back to reference Guo Y, Lang X, Lu Z, Wang J, Li T, Liao Y, et al. MiR-10b directly targets ZEB1 and PIK3CA to curb adenomyotic epithelial cell invasiveness via upregulation of e-cadherin and inhibition of Akt phosphorylation. Cell Physiol Biochem. 2015;35:2169–80.CrossRefPubMed Guo Y, Lang X, Lu Z, Wang J, Li T, Liao Y, et al. MiR-10b directly targets ZEB1 and PIK3CA to curb adenomyotic epithelial cell invasiveness via upregulation of e-cadherin and inhibition of Akt phosphorylation. Cell Physiol Biochem. 2015;35:2169–80.CrossRefPubMed
13.
go back to reference Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.CrossRefPubMed Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.CrossRefPubMed
15.
go back to reference Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed
16.
go back to reference Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral
17.
go back to reference Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMed Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMed
18.
go back to reference Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMed Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMed
19.
go back to reference Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35:499–515.CrossRefPubMed Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35:499–515.CrossRefPubMed
20.
go back to reference Fang Y, Sun B, Xiang J, Chen Z. MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiol Biochem. 2015;35:227–36.CrossRefPubMed Fang Y, Sun B, Xiang J, Chen Z. MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiol Biochem. 2015;35:227–36.CrossRefPubMed
21.
go back to reference Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentral Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentral
22.
go back to reference Gravgaard KH, Lyng MB, Laenkholm AV, Sokilde R, Nielsen BS, Litman T, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207–17.CrossRefPubMed Gravgaard KH, Lyng MB, Laenkholm AV, Sokilde R, Nielsen BS, Litman T, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207–17.CrossRefPubMed
23.
go back to reference Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, et al. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene. 2012;31:3051–9.CrossRefPubMed Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, et al. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene. 2012;31:3051–9.CrossRefPubMed
24.
go back to reference Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, Goodall GJ. The microRNA-200 family regulates epithelial to mesenchymal transition. Scientific World Journal. 2008;8:901–4.CrossRefPubMed Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, Goodall GJ. The microRNA-200 family regulates epithelial to mesenchymal transition. Scientific World Journal. 2008;8:901–4.CrossRefPubMed
25.
go back to reference von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.CrossRef von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.CrossRef
26.
go back to reference Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: MiR-200 suppresses metastases of colorectal cancer through ZEB1
Authors
Jiwei Sun
Wenjun Ding
Jiajun Zhi
Wei Chen
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3822-3

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine